Sunday, November 22, 2026
Via News Knowledge File

AbbVie Inc.

organization80% conf.·synced Aug 13, 2026

Biopharmaceutical company based in North Chicago, Illinois, developing oncology and hematology therapeutics

48
sourced metrics
521
relationships
20
stated objectives
5
Via News reports
Working data, not the finished story. This is what our AI has read and extracted from source documents so far. Before anything here becomes news, it is checked against the original source, fact-checked and put in context. Figures can be incomplete or wrongly labelled at this stage; our articles are the end product. How we source

Key metrics · each point sourced

Stock Price
$248.76
Aug 12, 2026reference only
Price 52 Week High
$263.3
Aug 12, 2026reference only
Stock Return Ytd
8.48%
Aug 12, 2026reference only
Price 52 Week Low
$197.38
Aug 12, 2026reference only
Net Income
$3.61B
Jun 30, 2026reference only
Capex
$587M
Jun 30, 2026reference only
Cash
$6.57B
Jun 30, 2026reference only
Stockholders Equity
-$5.93B
Jun 30, 2026reference only
Cost Of Revenue
$4.29B
Jun 30, 2026reference only
Total Assets
$135.12B
Jun 30, 2026reference only
Revenue
$16.99B
Jun 30, 2026reference only
Eps
2.03USD per share
Jun 30, 2026reference only
Operating Income
$6.43B
Jun 30, 2026reference only
Operating Cash Flow
$7.26B
Jun 30, 2026reference only
Consecutive Dividend Increases
53years
May 25, 2026source
Mid Late Stage Clinical Trials
60Mprograms
May 25, 2026source
Pipeline Total Programs
90Mprograms
May 25, 2026source
Portfolio Weight In Xlv
7.09%
May 18, 2026source

Stated objectives

Develop and commercialize 35+ investigational medicines in multiple clinical trials across hematologic cancers

source
target: 35 stated

Pursue additional international regulatory approvals for the R/R FL indication

source
stated

Evaluate epcoritamab as monotherapy and in combination across lines of therapy in a range of hematologic malignancies through four ongoing Phase 3 trials

source
stated

Achieve adjusted diluted EPS for 2025

source
target: 12.12 to 12.32 USD by 2025-12-31 00:00:00stated

Achieve high single-digit compound annual revenue growth rate for ex-Humira platform

source
target: high single-digit percent by 2029-12-31 00:00:00stated

Achieve combined sales of immunology duo

source
target: 27 billion USD by 2027-12-31 00:00:00stated

Raised full-year earnings guidance

source
target: $10.61-$10.65 EPS by 2025-12-31 00:00:00stated

High single-digit CAGR through 2029

source
target: high single-digit percent CAGR by 2029-01-01 00:00:00stated

Drive long-term growth through early-stage pipeline development

source
stated

Return to robust revenue growth following Humira LOE

source
by 2025-01-01 00:00:00stated

Relationship graph · 521 connections

Developed by
245
Competes with
48
Covered by
41
Headquartered in
30
Employs
27
Regulates
18
Acquired by
12
Invested in
10

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →